Forgot Password

Thank you for your request!

We will soon reach out to you.

Thank you for downloading..!

Contact us for more information.
Home » Healthcare » Pharmaceuticals » HPH-4151116

  • Global Multi Infarct Dementia Market Insights, Opportunity Analysis, Market Shares and Forecast, 2017 - 2023

  • Publish: November 2016 | Report Code: HPH-4151116

* For discount/customization and buying a particular chapter click here or write to us at [email protected]

The global multi-infarct dementia market is estimated to grow at a CAGR of 12.7% during 2016-2023. Multi infarct dementia is a common cause of memory loss among the elderly people between age group 55 to 75 years. Multi infarct dementia is caused multiple strokes to the brain it is also called as vascular dementia. According to National Institute of Health epidemiological study, multi infarct dementia accounts for over 20% dementia cases among people with age group above 65 years. Growing geriatric population in the world and increasing number of brain strokes would increase the incidence of multi infarct dementia. American Stoke Association, in its 2016 epidemiological report on stroke, estimated the global prevalence rate of stroke accounted for one in five per 1000 person. In U.S., nearly 800,000 people have a stroke every year, according to American Stroke Association. By 2030 stroke prevalence will increase around 20% more than 2012 levels. There are no viable treatment options for multi infarct dementia, other than early diagnosis and routine therapy.

Early diagnosis involves assessing individual cognitive ability, medical history, brain scans like computed topography (CT) or magnetic resonance imaging (MRI) scans. Changing regulatory compliance rules of different countries pose a challenge for market growth in the region. Increasing geriatric population, rising prevalence of strokes and increasing healthcare spending are the growth drivers discussed in multi-infarct dementia market research report. Emerging Economies and technological advancements in inhibitors are opportunities in deliberated in multi-infarct dementia market report for the forecasted period. Varying regulatory environment of different countries and unavailability of treatment therapy are the restraining issues discussed in multi infarct dementia market report. Lack of awareness about dementia as a disease is a challenge for the market growth period.

Source: OBRC Analysis

The research report is segmented on the basis of pharmacological treatment and causes of dementia.

The pharmacological treatment segment is further sub segmented into:

  • Cholinesterase Inhibitors
  • Memantine
  • Nimodipine
  • Hydergine





Cytidine 5’-Diphosphocholine (Cdp-Choline)

Other Drug Classes Like Selective Serotonin Reuptake Inhibitors, Calcium Channel Blockers, And Angiotensin-Converting-Enzyme Inhibitors.

Cholinesterase inhibitors are further divided into:

  • Donepezil
  • Galantamine
  • Rivastigmine




Causes of dementia are further classified into:

  • Anaemia
  • Brain Tumour
  • Chronic Infection
  • Depression
  • Thyroid Disease
  • Vitamin Deficiency
  • Drug Intoxication








The revenue for the above pharmacological treatment segments are specific to the global multi-infarct dementia market. However, the total revenue of these application and verticals in general has been excluded from the scope of the report.  

The research report analysed multi-infarct dementia market geographically. Region wise the report is segmented as

  • North America
  • Europe
  • Asia Pacific
  • Rest of the World





 Aging countries like Japan, Italy, Greece and Germany are the major markets for multi-infarct dementia. North America is the largest market for multi-infarct dementia market followed by Europe. Increasing cases of multi infarct dementia and growing geriatric population are the factors driving multi-infarct dementia market in the region. Multi-Infarct Dementia accounts for 30% of all dementia cases in North America and Europe. Asia Pacific is the fastest growing multi-infarct dementia market for the forecasted period. Rising geriatric population, increased healthcare spending, and changing healthcare reforms are the factors driving multi-infarct dementia market in the region for the forecasted period. Multi-Infarct dementia accounts for over 50% of the dementia cases in Japan.

The major market players of the global multi-infarct dementia market are:

  • Accelerys Inc.
  • Affymetrix Ltd.
  • Agilent Technologies
  • Celera Corporation
  • DNAexus Ltd.
  • Forest Laboratories Inc.
  • Geneva Bioinformatics.
  • GVK Biosciences Ltd.
  • IBM Life Science Ltd.
  • Illumina Inc.
  • Janssen Pharmaceuticals Inc
  • Life Technologies Corporation
  • Novartis Pharmaceutical Corporation
  • Pfizer Inc.
  • Siegen Inc.













Joint ventures, agreements, partnerships, collaborations, expansion in different countries, and strengthening supply chain network with distributors are some of the strategies taken by pioneers in multi-infarct dementia market, to increase their global presence. Research & development investments are high with the urge to develop quality and environmental friendly products.

Cytox and Affymetrix form partnership on 20th july 2015. This partnership is to develop and commercialize blood based genetic assay for research in diagnosis and prognosis of Alzheimer’s disease risk assessment and mild cognitive impairment (IMC).

Amarantus biosciences Inc., is currently undergoing its third phase clinical trials on drug Eltoprazine, after successful phase two trials on December 2015. Small pharmaceutical firms with unique and differentiated assets are driving innovation in multi-infarct dementia market. The report provides comprehensive information like company profile, sales, revenue, market share and contact information.

The report covers detailed analysis of companies which comprises of overview, SCOT analysis, product portfolio, strategic initiative, strategic analysis, competitive landscape and market share analysis in multi-infarct dementia market.

Key reason to buy the report:

  • The report includes market estimation, forecast and analysis for the year 2016-2023.
  • Report includes detailed analysis of different segments such as segmented on the basis of pharmacological treatment and causes of dementia.
  • Identify and understand the strength, opportunities, challenges and threat of the multi-infarct dementia market.
  • Covers detailed analysis of Porters 5 force model and other strategic models and also covers revenues, market share analysis, competitive landscape analysis of major players of global multi-infarct dementia market.
  • Detailed analysis of various the regulatory policies which are affecting the global multi-infarct dementia market.






How we are different from others:

At Occam’s we provide an extensive portfolio which is comprehensive market analysis along with the market size, market share, and market segmentations. Our report on global multi-infarct dementia market offers detailed analysis of strategic models such as investment vs. adoption model, see saw analysis and others strategic models. Also, the report contains the detailed analysis of application, adoption scenario and decision support for each segment. The report discusses competitive landscape of the multi- infarct dementia market, with giving extensive SCOT analysis of key companies. 

Key findings of the global multi- infarct dementia market:

  • Growing geriatric population in the world and increasing number of brain strokes is driving the multi- infarct dementia market.
  • North America has been the dominant market for multi infarct dementia in last two fiscal years (2015 & 2016) followed by Europe.
  • Asia Pacific and Latin America is the fastest growing multi infarct dementia market.
  • Cholinesterase Inhibitors is the major segment of pharmacological treatment segment.
  • Partnership and investment are the key strategy adopted by market players of global multi infarct dementia market. 
1.    INTRODUCTION
1.1.    EXECUTIVE SUMMARY
1.2.     ESTIMATION METHODOLOGY
 
2.    MARKET OVERVIEW
2.1.    GLOBAL MULTI-INFARCT DEMENTIA MARKET: EVOLUTION & TRANSITION
2.2.     MARKET DEFINITION & SCOPE
2.3.     INDUSTRY STRUCTURE
2.4.    REGULATORY FRAMEWORK
2.5.    TOTAL MARKET ANALYSIS
2.5.1.    TOP 5 FINDINGS
2.5.2.    TOP 5 OPPORTUNITY MARKETS
2.5.3.    TOP 5 COMPANIES
2.5.4.    TOP 3 COMPETITIVE STRATEGIES
2.6.    ESTIMATION ANALYSIS
2.7.    STRATEGIC ANALYSIS
2.7.1.    INVESTMENT VS. ADOPTION MODEL
2.7.2.    360 DEGREE INDUSTRY ANALYSIS
2.7.3.    PORTERS 5 FORCE MODEL
2.7.4.    SEE-SAW ANALYSIS
 
2.7.6.    CONSUMER ANALYSIS AND KEY BUYING CRITERIA
2.8.    COMPETITIVE ANALYSIS
2.8.1.    KEY STRATEGIES AND ANALYSIS
2.8.2.    MARKET SHARE ANALYSIS & TOP COMPANY ANALYSIS
 
2.9.    STRATEGIC RECOMMENDATIONS & KEY CONCLUSIONS
2.9.1.    INVESTMENT OPPORTUNITIES BY REGIONS
2.9.2.    OPPORTUNITIES IN EMERGING APPLICATIONS
2.9.3.    INVESTMENT OPPORTUNITY IN FASTEST GROWING SEGMENT
 
3.    MARKET DETERMINANTS
3.1.    MARKET DRIVERS & MARKET IMPACT
3.1.1.    INCREASING GERIATRIC POPULATION
3.1.2.    RISING PREVALENCE OF STROKES
3.1.3.    INCREASING HEALTHCARE SPENDING
3.1.4.    RISING DEMAND FOR DIAGNOSTIC PRODUCTS
3.1.5.    RISING INVESTMENT IN RESEARCH
3.2.    MARKET RESTRAINTS & MARKET IMPACT
3.2.1.    VARYING REGULATORY ENVIRONMENT OF DIFFERENT COUNTRIES
3.2.2.    UNAVAILABILITY OF TREATMENT THERAPY
3.2.3.    SUSTAINABILITY IN MARKET
3.3.    MARKET OPPORTUNITIES
3.3.1.    EMERGING ECONOMIES
3.3.2.    TECHNOLOGICAL ADVANCEMENTS IN INHIBITORS
3.4.    MARKET CHALLENGES
3.4.1.    LACK OF AWARENESS ABOUT DEMENTIA
3.4.2.    HIGH COST OF RESEARCH AND DEVELOPMENT
3.4.3.    INCREASING GERIATRIC MEDICINE MARKETS
 
4.    MARKET SEGMENTATION
4.1.    GLOBAL MULTI-INFARCT DEMENTIA MARKET BY PHARMACOLOGICAL TREATMENT  2014-2023 ($ MILLION)
4.1.1.    MARKET DEFINITION AND SCOPE
4.1.2.    DECISION SUPPORT DATABASE & ESTIMATION METHODOLOGY
4.1.3.    COMPARATIVE ANALYSIS ACROSS MARKET SEGMENTS
4.1.4.     OPPORTUNITY MATRIX
4.1.5.     MARKET SEGMENTATION
4.1.5.1.    CHOLINESTERASE INHIBITORS 2014-2023 ($ MILLION)
4.1.5.1.1.    APPLICATIONS
4.1.5.1.2.    ADOPTION SCENARIO & MARKET DETERMINANTS
4.1.5.1.3.    MARKET ESTIMATIONS AND FORECASTS  2014-2023 ($ MILLION)
4.1.5.1.4.    TOP PLAYERS & KEY PRODUCTS
4.1.5.1.5.    KEY CONCLUSIONS
4.1.5.1.6.    CHOLINESTERASE INHIBITORS BY SUB-SEGMENT
4.1.5.1.6.1.    DONEPEZIL
4.1.5.1.6.2.    GALANTAMINE
4.1.5.1.6.3.    RIVASTIGMINE
4.1.5.2.    MEMANTINE  2014-2023 ($ MILLION)
4.1.5.2.1.    APPLICATIONS
4.1.5.2.2.    ADOPTION SCENARIO & MARKET DETERMINANTS
4.1.5.2.3.    MARKET ESTIMATIONS AND FORECASTS  2014-2023 ($ MILLION)
4.1.5.2.4.    TOP PLAYERS & KEY PRODUCTS
4.1.5.2.5.    KEY CONCLUSIONS
4.1.5.3.    NIMODIPINE  2014-2023 ($ MILLION)
4.1.5.3.1.    APPLICATIONS
4.1.5.3.2.    ADOPTION SCENARIO & MARKET DETERMINANTS
4.1.5.3.3.    MARKET ESTIMATIONS AND FORECASTS  2014-2023 ($ MILLION)
4.1.5.3.4.    TOP PLAYERS & KEY PRODUCTS
4.1.5.3.5.    KEY CONCLUSIONS
4.1.5.4.    HYDERGINE  2014-2023 ($ MILLION)
4.1.5.4.1.    APPLICATIONS
4.1.5.4.2.    ADOPTION SCENARIO & MARKET DETERMINANTS
4.1.5.4.3.    MARKET ESTIMATIONS AND FORECASTS  2014-2023 ($ MILLION)
4.1.5.4.4.    TOP PLAYERS & KEY PRODUCTS
4.1.5.4.5.    KEY CONCLUSIONS
4.1.5.5.    CYTIDINE 5’-DIPHOSPHOCHOLINE (CDP-CHOLINE) 2014-2023 ($ MILLION)
4.1.5.5.1.    APPLICATIONS
4.1.5.5.2.    ADOPTION SCENARIO & MARKET DETERMINANTS
4.1.5.5.3.    MARKET ESTIMATIONS AND FORECASTS  2014-2023 ($ MILLION)
4.1.5.5.4.    TOP PLAYERS & KEY PRODUCTS
4.1.5.5.5.    KEY CONCLUSIONS
4.1.5.6.    OTHER DRUG CLASSES 2014-2023 ($ MILLION)
4.1.5.6.1.    APPLICATIONS
4.1.5.6.2.    ADOPTION SCENARIO & MARKET DETERMINANTS
4.1.5.6.3.    MARKET ESTIMATIONS AND FORECASTS  2014-2023 ($ MILLION)
4.1.5.6.4.    TOP PLAYERS & KEY PRODUCTS
4.1.5.6.5.    KEY CONCLUSIONS
4.2.    GLOBAL MULTI-INFARCT DEMENTIA MARKET BY CAUSES OF DEMENTIA  2014-2023 ($ MILLION)
4.2.1.    MARKET DEFINITION AND SCOPE
4.2.2.    DECISION SUPPORT DATABASE & ESTIMATION METHODOLOGY
4.2.3.    COMPARATIVE ANALYSIS ACROSS MARKET SEGMENTS
4.2.4.     OPPORTUNITY MATRIX
4.2.5.     MARKET SEGMENTATION
4.2.5.1.    ANAEMIA  2014-2023 ($ MILLION)
4.2.5.1.1.    APPLICATIONS
4.2.5.1.2.    ADOPTION SCENARIO & MARKET DETERMINANTS
4.2.5.1.3.    MARKET ESTIMATIONS AND FORECASTS  2014-2023 ($ MILLION)
4.2.5.1.4.    TOP PLAYERS & KEY PRODUCTS
4.2.5.1.5.    KEY CONCLUSIONS
4.2.5.2.    BRAIN TUMOR  2014-2023 ($ MILLION)
4.2.5.2.1.    APPLICATIONS
4.2.5.2.2.    ADOPTION SCENARIO & MARKET DETERMINANTS
4.2.5.2.3.    MARKET ESTIMATIONS AND FORECASTS  2014-2023 ($ MILLION)
4.2.5.2.4.    TOP PLAYERS & KEY PRODUCTS
4.2.5.2.5.    KEY CONCLUSIONS
4.2.5.3.    CHRONIC INFECTION  2014-2023 ($ MILLION)
4.2.5.3.1.    APPLICATIONS
4.2.5.3.2.    ADOPTION SCENARIO & MARKET DETERMINANTS
4.2.5.3.3.    MARKET ESTIMATIONS AND FORECASTS  2014-2023 ($ MILLION)
4.2.5.3.4.    TOP PLAYERS & KEY PRODUCTS
4.2.5.3.5.    KEY CONCLUSIONS
4.2.5.4.    DEPRESSION  2014-2023 ($ MILLION)
4.2.5.4.1.    APPLICATIONS
4.2.5.4.2.    ADOPTION SCENARIO & MARKET DETERMINANTS
4.2.5.4.3.    MARKET ESTIMATIONS AND FORECASTS  2014-2023 ($ MILLION)
4.2.5.4.4.    TOP PLAYERS & KEY PRODUCTS
4.2.5.4.5.    KEY CONCLUSIONS
4.2.5.5.    THYROID DISEASE  2014-2023 ($ MILLION)
4.2.5.5.1.    APPLICATIONS
4.2.5.5.2.    ADOPTION SCENARIO & MARKET DETERMINANTS
4.2.5.5.3.    MARKET ESTIMATIONS AND FORECASTS  2014-2023 ($ MILLION)
4.2.5.5.4.    TOP PLAYERS & KEY PRODUCTS
4.2.5.5.5.    KEY CONCLUSIONS
4.2.5.6.    VITAMIN DEFICIENCY  2014-2023 ($ MILLION)
4.2.5.6.1.    APPLICATIONS
4.2.5.6.2.    ADOPTION SCENARIO & MARKET DETERMINANTS
4.2.5.6.3.    MARKET ESTIMATIONS AND FORECASTS  2014-2023 ($ MILLION)
4.2.5.6.4.    TOP PLAYERS & KEY PRODUCTS
4.2.5.6.5.    KEY CONCLUSIONS
4.2.5.7.    DRUG INTOXICATION  2014-2023 ($ MILLION)
4.2.5.7.1.    APPLICATIONS
4.2.5.7.2.    ADOPTION SCENARIO & MARKET DETERMINANTS
4.2.5.7.3.    MARKET ESTIMATIONS AND FORECASTS  2014-2023 ($ MILLION)
4.2.5.7.4.    TOP PLAYERS & KEY PRODUCTS
4.2.5.7.5.    KEY CONCLUSIONS
 
5.    COMPETITIVE LANDSCAPE
5.1.    KEY STRATEGIES
5.1.1.    LIST OF MERGER &ACQUISITION
5.1.2.    LIST OF JOINT VENTURES
5.1.3.    LIST OF PRODUCT LAUNCHES
5.1.4.    LIST OF PARTNERSHIP
 
6.    GLOBAL MULTI-INFARCT DEMENTIA MARKET BY REGION (REVENUE ANALYSIS) 2014-2023 ($ MILLION)
6.1.    DECISION SUPPORT DATABASE & ESTIMATION METHODOLOGY
6.2.    COMPARATIVE ANALYSIS ACROSS MARKET SEGMENTS
6.3.    OPPORTUNITY MATRIX
6.4.     GEOGRAPHIC SEGMENTATION
6.4.1.    NORTH AMERICA
6.4.1.1.    INDUSTRY APPLICATION ANALYSIS
6.4.1.2.    TOP COUNTRY ANALYSIS
6.4.1.2.1.    U.S.
6.4.1.2.1.1.    MARKET ESTIMATIONS AND FORECASTS  2014-2023 ($ MILLION)
6.4.1.2.1.2.    MARKET REVENUES  2014-2023 ($ MILLION)
6.4.1.2.1.3.    PRICE ANALYSIS
6.4.1.2.1.4.    TOP PLAYERS & KEY PRODUCTS
6.4.1.2.1.5.    KEY CONCLUSIONS
6.4.1.2.2.    CANADA
6.4.1.2.2.1.    MARKET ESTIMATIONS AND FORECASTS  2014-2023 ($ MILLION)
6.4.1.2.2.2.    MARKET REVENUES  2014-2023 ($ MILLION)
6.4.1.2.2.3.    PRICE ANALYSIS
6.4.1.2.2.4.    TOP PLAYERS & KEY PRODUCTS
6.4.1.2.2.5.    KEY CONCLUSIONS
6.4.2.    EUROPE
6.4.2.1.    INDUSTRY APPLICATION ANALYSIS
6.4.2.2.    TOP COUNTRY ANALYSIS
6.4.2.2.1.    UK
6.4.2.2.1.1.    MARKET ESTIMATIONS AND FORECASTS  2014-2023 ($ MILLION)
6.4.2.2.1.2.    MARKET REVENUES  2014-2023 ($ MILLION)
6.4.2.2.1.3.    PRICE ANALYSIS
6.4.2.2.1.4.    TOP PLAYERS & KEY PRODUCTS
6.4.2.2.1.5.    KEY CONCLUSIONS
6.4.2.2.2.    FRANCE
6.4.2.2.2.1.    MARKET ESTIMATIONS AND FORECASTS  2014-2023 ($ MILLION)
6.4.2.2.2.2.    MARKET REVENUES  2014-2023 ($ MILLION)
6.4.2.2.2.3.    PRICE ANALYSIS
6.4.2.2.2.4.    TOP PLAYERS & KEY PRODUCTS
6.4.2.2.2.5.    KEY CONCLUSIONS
6.4.2.2.3.    GERMANY
6.4.2.2.3.1.    MARKET ESTIMATIONS AND FORECASTS  2014-2023 ($ MILLION)
6.4.2.2.3.2.    MARKET REVENUES  2014-2023 ($ MILLION)
6.4.2.2.3.3.    PRICE ANALYSIS
6.4.2.2.3.4.    TOP PLAYERS & KEY PRODUCTS
6.4.2.2.3.5.    KEY CONCLUSIONS
6.4.2.2.4.    REST OF EUROPE
6.4.2.2.4.1.    MARKET ESTIMATIONS AND FORECASTS  2014-2023 ($ MILLION)
6.4.2.2.4.2.    MARKET REVENUES  2014-2023 ($ MILLION)
6.4.2.2.4.3.    PRICE ANALYSIS
6.4.2.2.4.4.    TOP PLAYERS & KEY PRODUCTS
6.4.2.2.4.5.    KEY CONCLUSIONS
6.4.3.    ASIA PACIFIC
6.4.3.1.    INDUSTRY APPLICATION ANALYSIS
6.4.3.2.    TOP COUNTRY ANALYSIS
6.4.3.2.1.    CHINA
6.4.3.2.1.1.    MARKET ESTIMATIONS AND FORECASTS  2014-2023 ($ MILLION)
6.4.3.2.1.2.    MARKET REVENUES  2014-2023 ($ MILLION)
6.4.3.2.1.3.    PRICE ANALYSIS
6.4.3.2.1.4.    TOP PLAYERS & KEY PRODUCTS
6.4.3.2.1.5.    KEY CONCLUSIONS
6.4.3.2.2.    INDIA
6.4.3.2.2.1.    MARKET ESTIMATIONS AND FORECASTS  2014-2023 ($ MILLION)
6.4.3.2.2.2.    MARKET REVENUES  2014-2023 ($ MILLION)
6.4.3.2.2.3.    PRICE ANALYSIS
6.4.3.2.2.4.    TOP PLAYERS & KEY PRODUCTS
6.4.3.2.2.5.    KEY CONCLUSIONS
6.4.3.2.3.    JAPAN
6.4.3.2.3.1.    MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
6.4.3.2.3.2.    MARKET REVENUES 2014-2023 ($ MILLION)
6.4.3.2.3.3.    PRICE ANALYSIS
6.4.3.2.3.4.    TOP PLAYERS & KEY PRODUCTS
6.4.3.2.3.5.    KEY CONCLUSIONS
6.4.3.2.4.    REST OF ASIA PACIFIC
6.4.3.2.4.1.    MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
6.4.3.2.4.2.    MARKET REVENUES 2014-2023 ($ MILLION)
6.4.3.2.4.3.    PRICE ANALYSIS
6.4.3.2.4.4.    TOP PLAYERS & KEY PRODUCTS
6.4.3.2.4.5.    KEY CONCLUSIONS
6.4.4.    REST OF THE WORLD
6.4.4.1.    INDUSTRY APPLICATION ANALYSIS
6.4.4.2.    TOP COUNTRY ANALYSIS
6.4.4.2.1.    LATIN AMERICA
6.4.4.2.1.1.    MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
6.4.4.2.1.2.    MARKET REVENUES 2014-2023 ($ MILLION)
6.4.4.2.1.3.    PRICE ANALYSIS
6.4.4.2.1.4.    TOP PLAYERS & KEY PRODUCTS
6.4.4.2.1.5.    KEY CONCLUSIONS
6.4.4.2.2.    MIDDLE EAST & AFRICA
6.4.4.2.2.1.    MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
6.4.4.2.2.2.    MARKET REVENUES 2014-2023 ($ MILLION)
6.4.4.2.2.3.    PRICE ANALYSIS
6.4.4.2.2.4.    TOP PLAYERS & KEY PRODUCTS
6.4.4.2.2.5.    KEY CONCLUSIONS
6.4.4.2.3.    AFRICA
6.4.4.2.3.1.    MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
6.4.4.2.3.2.    MARKET REVENUES 2014-2023 ($ MILLION)
6.4.4.2.3.3.    PRICE ANALYSIS
6.4.4.2.3.4.    TOP PLAYERS & KEY PRODUCTS
6.4.4.2.3.5.    KEY CONCLUSIONS
 
7.    COMPANY PROFILES
7.1.    ACCELERYS INC.
7.1.1.    OVERVIEW
7.1.2.    PRODUCT PORTFOLIO
7.1.3.    KEY INNOVATION SECTOR
7.1.4.    STRATEGIC INITIATIVES
7.1.5.    SCOT ANALYSIS
7.2.    AFFYMETRIX
7.2.1.    OVERVIEW
7.2.2.    PRODUCT PORTFOLIO
7.2.3.    KEY INNOVATION SECTOR
7.2.4.    STRATEGIC INITIATIVES
7.2.5.    SCOT ANALYSIS
7.3.    AGILENT TECHNOLOGIES
7.3.1.    OVERVIEW
7.3.2.    PRODUCT PORTFOLIO
7.3.3.    KEY INNOVATION SECTOR
7.3.4.    STRATEGIC INITIATIVES
7.3.5.    SCOT ANALYSIS
7.4.    CELERA CORPORATION
7.4.1.    OVERVIEW
7.4.2.    PRODUCT PORTFOLIO
7.4.3.    KEY INNOVATION SECTOR
7.4.4.    STRATEGIC INITIATIVES
7.4.5.    SCOT ANALYSIS
7.5.    DNANEXUS
7.5.1.    OVERVIEW
7.5.2.    PRODUCT PORTFOLIO
7.5.3.    KEY INNOVATION SECTOR
7.5.4.    STRATEGIC INITIATIVES
7.5.5.    SCOT ANALYSIS
7.6.    FOREST LABORATORIES INC.,
7.6.1.    OVERVIEW
7.6.2.    PRODUCT PORTFOLIO
7.6.3.    KEY INNOVATION SECTOR
7.6.4.    STRATEGIC INITIATIVES
7.6.5.    SCOT ANALYSIS
7.7.    GENEVA BIOINFORMATICS
7.7.1.    OVERVIEW
7.7.2.    PRODUCT PORTFOLIO
7.7.3.    KEY INNOVATION SECTOR
7.7.4.    STRATEGIC INITIATIVES
7.7.5.    SCOT ANALYSIS
7.8.    GVK BIOSCIENCES
7.8.1.    OVERVIEW
7.8.2.    PRODUCT PORTFOLIO
7.8.3.    KEY INNOVATION SECTOR
7.8.4.    STRATEGIC INITIATIVES
7.8.5.    SCOT ANALYSIS
7.9.    IBM LIFE SCIENCES
7.9.1.    OVERVIEW
7.9.2.    PRODUCT PORTFOLIO
7.9.3.    KEY INNOVATION SECTOR
7.9.4.    STRATEGIC INITIATIVES
7.9.5.    SCOT ANALYSIS
7.10.    ILLUMINA INC.
7.10.1.    OVERVIEW
7.10.2.    PRODUCT PORTFOLIO
7.10.3.    KEY INNOVATION SECTOR
7.10.4.    STRATEGIC INITIATIVES
7.10.5.    SCOT ANALYSIS
7.11.    JANSSEN PHARMACEUTICALS INC.,
7.11.1.    OVERVIEW
7.11.2.    PRODUCT PORTFOLIO
7.11.3.    KEY INNOVATION SECTOR
7.11.4.    STRATEGIC INITIATIVES
7.11.5.    SCOT ANALYSIS
7.12.    LIFE TECHNOLOGIES CORPORATION
7.12.1.    OVERVIEW
7.12.2.    PRODUCT PORTFOLIO
7.12.3.    KEY INNOVATION SECTOR
7.12.4.    STRATEGIC INITIATIVES
7.12.5.    SCOT ANALYSIS
7.13.    NOVARTIS PHARMACEUTICAL CORPORATION
7.13.1.    OVERVIEW
7.13.2.    PRODUCT PORTFOLIO
7.13.3.    KEY INNOVATION SECTOR
7.13.4.    STRATEGIC INITIATIVES
7.13.5.    SCOT ANALYSIS
7.14.    PFIZER INC.,
7.14.1.    OVERVIEW
7.14.2.    PRODUCT PORTFOLIO
7.14.3.    KEY INNOVATION SECTOR
7.14.4.    STRATEGIC INITIATIVES
7.14.5.    SCOT ANALYSIS
7.15.    SIEGEN INC.,
7.15.1.    OVERVIEW
7.15.2.    PRODUCT PORTFOLIO
7.15.3.    KEY INNOVATION SECTOR
7.15.4.    STRATEGIC INITIATIVES
7.15.5.    SCOT ANALYSIS
 
LIST OF TABLES
 
1.    GLOBAL  MULTI INFARCT DEMENTIA  MARKET BY PHARMACOLOGICAL TREATMENT 2014-2023 ($ MILLION)
2.    GLOBAL CHOLINESTERASE INHIBITORS MARKET BY GEOGRAPHY 2014-2023 ($ MILLION)
3.    GLOBAL DONEPEZIL MARKET BY GEOGRAPHY 2014-2023 ($ MILLION)
4.    GLOBAL GALANTAMINE MARKET BY GEOGRAPHY 2014-2023 ($ MILLION)
5.    GLOBAL RIVASTIGMINE MARKET BY GEOGRAPHY 2014-2023 ($ MILLION)
6.    GLOBAL MEMANTINE MARKET BY GEOGRAPHY 2014-2023 ($ MILLION)
7.    GLOBAL NIMODIPINE MARKET BY GEOGRAPHY 2014-2023 ($ MILLION)
8.    GLOBAL HYDERGINE MARKET BY GEOGRAPHY 2014-2023 ($ MILLION)
9.    GLOBAL CYTIDINE 5’-DIPHOSPHOCHOLINE (CDP-CHOLINE) MARKET BY GEOGRAPHY 2014-2023 ($ MILLION)
10.    GLOBAL OTHER DRUG CLASSES MARKET BY GEOGRAPHY 2014-2023 ($ MILLION)
11.    GLOBAL MULTI INFARCT DEMENTIA BY CAUSES OF DEMENTIA 2014-2023 ($ MILLION)
12.    GLOBAL MULTI INFARCT DEMENTIA BY ANEMIA BY GEOGRAPHY 2014-2023 ($ MILLION)
13.    GLOBAL MULTI INFARCT DEMENTIA BY BRAIN TUMOR BY GEOGRAPHY 2014-2023 ($ MILLION)
14.    GLOBAL MULTI INFARCT DEMENTIA BY CHRONIC INFECTION BY GEOGRAPHY 2014-2023 ($ MILLION)
15.    GLOBAL MULTI INFARCT DEMENTIA BY DEPRESSION BY GEOGRAPHY 2014-2023 ($ MILLION)
16.    GLOBAL MULTI INFARCT DEMENTIA BY THYROID DISEASE BY GEOGRAPHY 2014-2023 ($ MILLION)
17.    GLOBAL MULTI INFARCT DEMENTIA BY VITAMIN DEFICIENCY BY GEOGRAPHY 2014-2023 ($ MILLION)
18.    GLOBAL MULTI INFARCT DEMENTIA BY DRUG INTOXICATION BY GEOGRAPHY 2014-2023 ($ MILLION)
19.    NORTH AMERICA MULTI INFARCT DEMENTIA 2014-2023 ($ MILLION)
20.    EUROPE MULTI INFARCT DEMENTIA 2014-2023 ($ MILLION)
21.    ASIA PACIFIC MULTI INFARCT DEMENTIA 2014-2023 ($ MILLION)
22.    REST OF THE WORLD MULTI INFARCT DEMENTIA 2014-2023 ($ MILLION)
 
LIST OF FIGURES
 
1.    GLOBAL MULTI INFARCT DEMENTIA BY CHOLINESTERASE INHIBITORS 2014-2023 ($ MILLION)
2.    GLOBAL MULTI INFARCT DEMENTIA BY DONEPEZIL 2014-2023 ($ MILLION)
3.    GLOBAL MULTI INFARCT DEMENTIA BY GALANTAMINE 2014-2023 ($ MILLION)
4.    GLOBAL MULTI INFARCT DEMENTIA BY RIVASTIGMINE 2014-2023 ($ MILLION)
5.    GLOBAL MULTI INFARCT DEMENTIA BY MEMANTINE 2014-2023 ($ MILLION)
6.    GLOBAL MULTI INFARCT DEMENTIA BY NIMODIPINE 2014-2023 ($ MILLION)
7.    GLOBAL MULTI INFARCT DEMENTIA BY HYDERGINE 2014-2023 ($ MILLION)
8.    GLOBAL MULTI INFARCT DEMENTIA BY CYTIDINE 5’-DIPHOSPHOCHOLINE (CDP-CHOLINE) 2014-2023 ($ MILLION)
9.    GLOBAL MULTI INFARCT DEMENTIA BY ANEMIA 2014-2023 ($ MILLION)
10.    GLOBAL MULTI INFARCT DEMENTIA BY BRAIN TUMOR 2014-2023 ($ MILLION)
11.    GLOBAL MULTI INFARCT DEMENTIA BY CHRONIC INFECTION 2014-2023 ($ MILLION)
12.    GLOBAL MULTI INFARCT DEMENTIA BY DEPRESSION 2014-2023 ($ MILLION)
13.    GLOBAL MULTI INFARCT DEMENTIA BY THYROID DISEASE 2014-2023 ($ MILLION)
14.    GLOBAL MULTI INFARCT DEMENTIA BY VITAMIN DEFICIENCY 2014-2023 ($ MILLION)
15.    GLOBAL MULTI INFARCT DEMENTIA BY DRUG INTOXICATION 2014-2023 ($ MILLION)
16.    UNITED STATES (U.S.) MULTI INFARCT DEMENTIA 2014-2023 ($ MILLION)
17.    CANADA MULTI INFARCT DEMENTIA 2014-2023 ($ MILLION)
18.    UNITED KINGDOM (UK) MULTI INFARCT DEMENTIA 2014-2023 ($ MILLION)
19.    FRANCE MULTI INFARCT DEMENTIA 2014-2023 ($ MILLION)
20.    GERMANY MULTI INFARCT DEMENTIA 2014-2023 ($ MILLION)
21.    ROE MULTI INFARCT DEMENTIA 2014-2023 ($ MILLION)
22.    INDIA MULTI INFARCT DEMENTIA 2014-2023 ($ MILLION)
23.    CHINA MULTI INFARCT DEMENTIA 2014-2023 ($ MILLION)
24.    JAPAN MULTI INFARCT DEMENTIA 2014-2023 ($ MILLION)
25.    ROAPAC MULTI INFARCT DEMENTIA 2014-2023 ($ MILLION)
26.    LATIN AMERICA MULTI INFARCT DEMENTIA 2014-2023 ($ MILLION)
27.    MENA MULTI INFARCT DEMENTIA 2014-2023 ($ MILLION)
28.    AFRICA MULTI INFARCT DEMENTIA 2014-2023 ($ MILLION)
 

FAQ

How can I purchase a report?
We offer an easy way to purchase any report of your choice from various domains that we offer. You can easily search for your desired reports by simply using the search bar on our website's home page. For multiple purchases, you can add reports to the shopping cart, fill a detail form and check out. We accept payments though authentic and trusted payment gateways which accept all major credit cards.
How safe is to use my credit card? Is my information secure?
We ensure complete safety to all online transactions made by credit cards. We use most secure encryption technology available today for the electronic transactions and all our credit card sales are secured with an SSL technology. Your information is highly secure and confidential.
Can I get a discount?
We send discount offers through email as per your request. In case you would like to receive discounts, please sign up for our newsletter.
I want to buy only a chapter. I don't need complete report.
Yes you can buy your desired chapter/page or the entire report, by just clicking on the table of contents in any report and selecting chapter of your interest. We do have separate pricing for chapters/reports/excel sheets/presentation pages etc.
Can I get reports on my desired topic specially which is not available in your current portfolio?
Do call us or mail us the topic of your preference. Our dedicated team on analysts will prepare a report as per your preference and requirements.
When do I get access to the report(s) that I have purchased?
We will email you your purchased report right after we receive your payment through any of the payment options.
Will I receive any invoice for my purchase?
Yes we will email you invoice/payment confirmation with the order details once we receive your payment.
In what format will the reports be available in?
All the reports will be available in PDF format for download.

Request for Sample
Select License Type
Required More Information

0731 4042636

+91 9713031393

UPCOMING REPORTS

No upcoming reports available under this subcategory.

NAVIGATION LINK

OUR SERVICES

credit card

CONNECT WITH US

Occams Business Research & Consulting Pvt. Ltd.

Landline: 0731 4042636 

Handheld: +91 9713031393

Email: [email protected]

 

 

  • facebook
  • twitter
  • blog
  • linkdin
  • google plus
  • youtube
Go To Top
viewthroughconversion